Imagine a smart assistant that scans a patient's entire body for cancer instead of looking at just one organ at a time. It acts like an automated highlighter, marking tumors and measuring them instantly so doctors don't have to do it by hand. This removes the tedious paperwork and manual measuring, letting doctors focus on treating the patient.
Radiologists are facing burnout and increasing misdiagnosis risks due to a global shortage of specialists and a rising volume of cancer cases. They spend excessive time on manual, repetitive tasks like measuring lesions on CT scans.
An AI-powered full-body cancer detection and monitoring system that automates lesion measurement and data labeling using deep learning.
If you are a diagnostic center dealing with a shortage of radiologists and rising cancer cases — this project developed an AI tool that reduces the time spent interpreting CT scans by 40-60%. This allows your clinic to process more patients without increasing staff burnout.
If you are a medical software provider dealing with outdated manual lesion measurement tools — this project developed a full-body AI detection system that automates data labeling and tumor tracking. This adds a high-value automated diagnostic layer to your existing imaging software.
If you are a public hospital dealing with a 27.4% expected increase in cancer cases over the next decade — this project developed an AI-powered monitoring system that streamlines workflows. This prevents misdiagnosis and delays in critical cancer care.
Based on available project data, specific pricing or cost details for the end-user are not provided.
Yes, the system is designed to address a global shortage of radiologists and a rising cancer incidence, suggesting a scalable software-as-a-service model for healthcare systems.
Based on available project data, the project is led by Better Medicine OU, but specific licensing terms are not detailed in the summary.
The tool automates repetitive tasks like measuring and classifying lesions on CT scans, aiming to reduce interpretation time by 40-60%.
The project period is from 2024-01-01 to 2026-06-30, indicating the development and validation phase ends in mid-2026.
The project is managed by a single-partner consortium consisting of one Estonian SME, Better Medicine OU. This 100% industry-led structure suggests a highly focused, commercially driven development cycle without the academic overhead of university partners, aiming for rapid productization.
Contact Better Medicine OU in Estonia
Contact us to explore licensing or partnership opportunities with Better Medicine OU.
